Resources about TB
and TB Vaccine R&D
- Meeting Report: 6th Global Forum on TB Vaccines, 22 - 25 February 2022, published open access in Vaccine: X
- TB Vaccines Pipeline Report is a report from Treatment Action Group (TAG) that reviews progress in the clinical development of TB vaccines. The report is updated annually.
- Platforms in the TB Vaccine Pipeline provides an overview of the different platforms - or types of vaccines - in the TB vaccine pipeline
- Global Tuberculosis Report, published by the WHO, provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease at global, regional and country levels. The report is updated annually.
- WHO Preferred Product Characteristics for New Tuberculosis Vaccine presents WHO preferences for new tuberculosis vaccines, driven by the high medical need for contribution to the fight against TB, in alignment with the End TB strategy.
- TB Vaccine Development Pathway, developed by IAVI and TBVI, is an online tool that provides a structured development path and gating criteria for TB vaccine candidates. It includes considerations for target populations, vaccine platforms, and market, access and implementation, as well as guidance for planning and operating community engagement activities.
- BCG World Atlas is an interactive map that provides detailed information on current and past BCG vaccination policies and practices for over 180 countries.
Resources for Advocacy, Policy, and Funding
- End TB Strategy from the World Health Organization’s Global TB Programme provides a 20-year strategy toward the goal of ending the TB epidemic, including research, development, and implementation of new tools.
- Global Plan to End TB 2023-2030 is a costed plan and roadmap for a concerted response to tuberculosis (TB) aligned with the WHO End TB Strategy, including a strategic framework for TB vaccine R&D.
- Report on Tuberculosis Research Funding Trends, published annually by TAG, tracks how much public, private, philanthropic, and multilateral institutions spend on TB research and development (R&D) across six areas of research: basic science, diagnostics, drugs vaccines, operational research, and infrastructure/unspecified projects.
- An investment case for new TB vaccines summarizes the results of a full value proposition for new tuberculosis (TB) vaccines commissioned by WHO to provide early evidence for national and global decision-makers involved in TB vaccine development and implementation, who include stakeholders involved in vaccine research, financing, regulation and policy-making, manufacturing, introduction and procurement. A Q&A on how this work can be best used for TB vaccine advocacy is available here.
- Words Matter, published by Stop TB Partnership, is a communications tool for partners, stakeholders, and anyone affected or working in TB. The guide is a key instrument to encourage positive change, sensitize, promote appropriate language, end the stigmatization, and empower people affected by TB.
- New TB vaccines needed to tackle AMR shares a collective call to decision-makers to prioritize TB vaccine R&D as a signature piece of global health and antimicrobial resistance (AMR) agendas. The brief, from the TB Vax ARM, draws on the latest research in health and economic modelling to demonstrate how new TB vaccines could significantly help control drug-resistant TB, in a cost-effective and affordable way.
- The Urgent Need for New TB Vaccines, published by the TB Vaccine Advocacy Roadmap (TBVaxARM), provides information and talking points about the importance of TB vaccines to meeting global targets to end TB and the need to invest in TB vaccine research and development.
- Modeling in TB vaccine development provides an overview of mathematical modeling for TB vaccines, like public health impact and cost-effective modeling, and how modeling can be used to support TB vaccine advocacy efforts.
- A Deadly Divide: TB Commitments vs TB Realities. Developed by the Stop TB Partnership Communities, Developing Country NGO and Developed Country NGO Delegations to the Board through consultation with their constituents and other key stakeholders, this report documents how – two years on from the United Nations High-Level Meeting on TB and the Political Declaration on the Fight Against Tuberculosis – there is a major gap between the targets endorsed by heads of state and governments, and the results achieved.
- Video - Phumeza Tisile talk about her challenges in facing extensively drug-resistant TB, her vision of a TB free world, and how we can achieve it with new TB vaccines.
- Joint Statement: WHO Director-General and the Civil Society Task Force on TB, a call for increased political commitment and accountability in preparation for the 2023 UN High-Level Meeting on Tuberculosis.
- TB Research Investments Provide Returns in Combating Both TB and COVID-19 is a policy brief published by Treatment Action Group (TAG) that explores the impact of COVID-19 on TB research and development (R&D), and how tools, concepts, capacity, and infrastructure established through years of public and donor investments in TB R&D have informed and jump-started COVID-19 research and responses.
Contact us if you have resources related to advocacy, policy, and funding for TB vaccine R&D that you would like to share.
Resources for Community Engagement
- Good Participatory Practice Guidelines for TB Vaccine Research, published by Aeras, is a user- friendly framework that defines specific standards and key elements needed for creating effective partnerships with stakeholders throughout the entire research process.
- Frequently Asked Questions on TB Vaccine Research, published by IAVI, is a fact sheet that provides information and answers to commonly asked questions about TB vaccine research.
- Myths and Facts about TB Vaccine Research, by IAVI, is a fact sheet that responds to some common misconceptions about vaccine research.
- Tuberculosis Vaccines and Clinical Trials, published by IAVI, provides information about TB, vaccines, and clinical trials in an illustrative and easy to understand booklet.
- Being Part of Tuberculosis Vaccine Clinical Trials is a speaking book published by Books of Hope in collaboration with Aeras, that provides potential clinical trial participants with information about tuberculosis and what is involved in participating in a clinical trial. The information is in both English and Afrikaans.
Recent Scientific Publications
- The role of bacterial vaccines in the fight against antimicrobial resistance: an analysis of the preclinical and clinical development pipeline. Frost I, Sati H, Garcia-Vello P, Hasso-Agopsowicz M, Lienhardt C, Gigante V, Beyer P. Lancet Microbe. 2023 Feb. doi: 10.1016/S2666-5247(22)00303-2. Epub 2022 Dec 14.
- Characterization of natural killer cells in the blood and airways of cynomolgus macaques during Mycobacterium tuberculosis infection. Diedrich CR, Rutledge T, Baranowski TM, Maiello P, Lin PL. J Med Primatol. 2023 Feb. doi: 10.1111/jmp.12617. Epub 2022 Sep 3.
- Surveillance of Daughter Micronodule Formation Is a Key Factor for Vaccine Evaluation Using Experimental Infection Models of Tuberculosis in Macaques. Nogueira I, Català M, White AD, Sharpe SA, Bechini J, Prats C, Vilaplana C, Cardona P. Pathogens. 2023 Feb 2. doi: 10.3390/pathogens12020236.
- Mycobacterium tuberculosis Evasion of Guanylate Binding Protein-Mediated Host Defense in Mice Requires the ESX1 Secretion System. Olive AJ, Smith CM, Baer CE, Coers J, Sassetti CM. Int J Mol Sci. 2023 Feb 2. doi: 10.3390/ijms24032861.
- Report of 16 Years of the BCG Vaccine under the Expanded Program on Immunizations in Mexico (2006-2021). Romero-Feregrino R, Romero-Cabello R, Rodríguez-León MA, Romero-Feregrino R, Muñoz-Cordero B, Aguilar-Feregrino JI. Vaccines (Basel). 2023 Feb 2. doi: 10.3390/vaccines11020337.
- Finding TB vaccine antigens: follow the TCRs. Lichtman A. Sci Immunol. 2023 Feb 3. doi: 10.1126/sciimmunol.adg8281. Epub 2023 Feb 3.
- Pulmonary Administration of the Liposome-Based Adjuvant CAF01: Effect of Surface Charge on Mucosal Adjuvant Function. Müllertz OAO, Andersen P, Christensen D, Foged C, Thakur A. Mol Pharm. 2023 Feb 6. doi: 10.1021/acs.molpharmaceut.2c00634. Epub 2022 Dec 30.
- Recombinant Pichinde viral vector expressing tuberculosis antigens elicits strong T cell responses and protection in mice. Kirk NM, Huang Q, Vrba S, Rahman M, Block AM, Murphy H, White DW, Namugenyi SB, Ly H, Tischler AD, Liang Y. Front Immunol. 2023 Feb 8. doi: 10.3389/fimmu.2023.1127515. eCollection 2023
- Editorial: Research advances of tuberculosis vaccine and its implication on COVID-19. Gong W, Xie J, Li H, Aspatwar A. Front Immunol. 2023 Feb 9. doi: 10.3389/fimmu.2023.1147704. eCollection 2023.
- Preclinical developments in the delivery of protein antigens for vaccination. Hendy DA, Haven A, Bachelder EM, Ainslie KM. Expert Opin Drug Deliv. 2023 Feb 10. doi: 10.1080/17425247.2023.2176844. Online ahead of print.
- BCG-induced trained immunity: history, mechanisms and potential applications. Chen J, Gao L, Wu X, Fan Y, Liu M, Peng L, Song J, Li B, Liu A, Bao F. J Transl. Med. 2023 Feb 10. doi: 10.1186/s12967-023-03944-8.
- Genome sequences of BCG Pasteur ATCC 35734 and its derivative, the vaccine candidate BCGΔBCG1419c. D’Auria G, Hodzhev Y, Aceves-Sánchez MJ, Moya A, Panaiotov S, Flores-Valdez MA. BMC Genomics. 2023 Feb 10. doi: 10.1186/s12864-023-09169-9.
- Design of multi-epitope based vaccine against Mycobacterium tuberculosis: a subtractive proteomics and reverse vaccinology based immunoinformatics approach. Nayak SS, Sethi G, Ramadas K. J Biomol Struct Dyn. 12 Feb 2023. doi: 10.1080/07391102.2023.2178511. Online ahead of print.
- Mycobacterium bovis BCG Given at Birth Followed by Inactivated Respiratory Syncytial Virus Vaccine Prevents Vaccine-Enhanced Disease by Promoting Trained Macrophages and Resident Memory T Cells. Wang Y, Ge F, Wang J, Li H, Zheng B, Li W, Chen S, Zheng X, Deng Y, Wang Y, Zeng R. J Virol. 2023 Feb 13. doi: 10.1128/jvi.01764-22. Online ahead of print.
- Preventive effects of Mycobacterium tuberculosis DNA vaccines on the mouse model with latent tuberculosis infection. Liang Y, Li X, Yang Y, Xiao L, Liang Y, Mi J, Xue Y, Gong W, Wang L, Wang J, Zhang J, Shi Y, Peng B, Chen X, Zhao W, Wu X. Front Immunol. 2023 Feb 13. doi: 10.3389/fimmu.2023.1110843.
- A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase TB Trials. Kurbatova EV, Phillips PP, Dorman SE, Sizemore EE, Bryant KE, Purfield AE, Ricaldi J, Brown NE, Johnson JL, Wallis CL, Akol JP, Ocheretina O, Hung NV, Mayanja-Kizza H, Lourens M, Dawson R, Nhung NV, Pierre S, Musodza Y, Shenje J, Badal-Faesen S, Vilbrun SC, Waja Z, Peddareddy L, Scott NA, Yuan Y, Vernon A, Goldberg SV, Swindells S, Chaisson RE, Nahid P, AIDS Clinical Trials Group and the Tuberculosis Trials Consortium. AM J Respir Crit Care Med. 2023 Feb 15. doi: 10.1164/rccm.202206-1118OC. Online ahead of print.
- Meeting Summary: Global Vaccine and Immunization Research Forum, 2021. Ford A, Hwang A, Mo AX, Baqar S, Touchette N, Deal C, King D, Earle K, Giersing B, Dull P, Hall BF. Vaccine. 2023 Feb 18. doi: 10.1016/j.vaccine.2023.02.028. Online ahead of print.
- Long-Term Immunogenicity and In Vitro Prophylactic Protective Efficacy of M. tuberculosis Fusion Protein DR2 Combined with Liposomal Adjuvant DIMQ as a Boosting Vaccine for BCG. Mao L, Du J, Wang X, Xu L, Zhang Y, Sun Q, Shi Z, Xing Y, Su Y, Wang S, Wang J, Ma J, Zhang J. ACS Infect Dis. 2023 Feb 21. doi: 10.1021/acsinfecdis.2c00570. Online ahead of print.
- Intranasal multivalent adenoviral-vectored vaccine protects against replicating and dormant M.tb in conventional and humanized mice. Afkhami S, D’Agostino MR, Vaseghi-Shanjani M, Lepard M, Yang JX, Lai R, Wa Yan Choi M, Chacon A, Zganiacz A, Franken KLMC, Ertl HE, Ottenhoff THM, Jeyanathan M, Gillgrass A, Xing Z. NPJ Vaccines. 2023 Feb 23. doi: 10.1038/s41541-023-00623-z.
- Newborn BCG vaccination induces robust infant IFNγ-expressing NK cell responses to mycobacteria. Murphy M, Suliman S, Briel L, Veldtsman H, Khomba N, Africa H, Steyn M, Snyders CI, van Rensburg IC, Walzl G, Chegou NN, Hatherill M, Hanekom WA, Scriba TJ, Nemes E. Int J Infect Dis. 2023 Feb 24. doi: 10.1016/j.ijid.2023.02.018. Online ahead of print.
- Safety and efficacy of tuberculosis vaccine candidates in low– and middle-income countries: a systematic review of randomized controlled clinical trials. Wilson L, Gracie L, Kidy F, Thomas GN, Nirantharakumar K, Greenfield S, Manaseki-Holland S, Ward, DJ, Gooden, TE. BMC Infec Dis. 2023 Feb 24. doi: 10.1186/s12879-023-08092-4.
- New tuberculosis vaccines in India: Modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01 E and BCG-revaccination. Weerasuriya CK, Portnoy A, Mukandavire C, Quaife M, Bakker R, Scarponi D, Harris RC, Rade K, Mattoo SK, Tumu D, Menzies NA, White RG. medRxiv. 2023 Feb 24. doi: 10.1101/2023.02.24.23286406. Preprint
- Antibodies Targeting the Cell Wall Induce Protection against Virulent Mycobacterium bovis Infection. Qu M, Liang Z, Chen Y, Wang Y, Wang H, Liu Z, Liu Y, Dong Y, Ge X, Li H, Zhou X. Microbiol Spectr. 2023 Feb 27. doi: 10.1128/spectrum.03431-22. Online ahead of print.
- A MAPS Vaccine Induces Multipronged Systemic and Tissue-Resident Cellular Responses and Protects Mice against Mycobacterium tuberculosis. O’Hara JM, Wakabayashi S, Siddiqi N, Cheung E, Babunovic GH, Thompson CM, Lu Y, Rubin EJ, Malley R, Zhang F. mBio. 2023 Feb 28. doi: 10.1128/mbio.03611-22.
- Spotlight on mycobacterial lipid exploitation using nanotechnology for diagnosis, vaccines, and treatments. Valdemar-Aguilar CM, Manisekaran R, Acosta-Torres LS, López-Marín LM. Nanomedicine. 2023 Feb. doi: 10.1016/j.nano.2023.
Contact us with recent publications (within last 30 days) sharing new data, approaches, and information on TB vaccine R&D